Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN
Jinzhou Liu,
Min Guo,
Xiaobin Yuan,
Xiao Fan,
Jin Wang,
Xiangying Jiao,
Jinzhou Liu
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorMin Guo
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorXiaobin Yuan
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China
Search for more papers by this authorXiao Fan
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China
Search for more papers by this authorJin Wang
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorCorresponding Author
Xiangying Jiao
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Correspondence:
Xiangying Jiao ([email protected])
Search for more papers by this authorJinzhou Liu,
Min Guo,
Xiaobin Yuan,
Xiao Fan,
Jin Wang,
Xiangying Jiao,
Jinzhou Liu
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorMin Guo
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorXiaobin Yuan
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China
Search for more papers by this authorXiao Fan
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China
Search for more papers by this authorJin Wang
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Search for more papers by this authorCorresponding Author
Xiangying Jiao
Department of Physiology, The Key Laboratory of Physiology of Shanxi Province, the Key Laboratory of Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan, China
Correspondence:
Xiangying Jiao ([email protected])
Search for more papers by this authorFunding: This work was supported by the Open Access Fund from Shanxi Key Laboratory of Big Data for Clinical Decision Research, 2023-2, Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province, 20240047, Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project, BYJL009, and Natural Science Foundation of Shanxi Province, 202103021223232, 202303021211120.
Jinzhou Liu and Min Guo contributed equally to this work and share first authorship.
ABSTRACT
Background
Diabetic nephropathy (DN) is a severe microvascular complication of diabetes with a complex pathogenesis.
Methods
Recent studies were reviewed to explore the role of gut microbiota and its metabolites in DN development.
Results
Dysbiosis of gut bacteria contributes to pathological changes such as glomerular sclerosis and renal tubule injury. Microbial metabolites are involved in DN through immune and inflammatory pathways.
Conclusions
Understanding the relationship between gut microbiota, its metabolites, and DN may offer potential implications for DN diagnosis, prevention, and treatment. Translating this knowledge into clinical practice presents challenges and opportunities.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability Statement
Data will be made available on request.
Supporting Information
| Filename | Description |
|---|---|
| jdb70068-sup-0001-Supinfo.docxWord 2007 document , 12.5 KB |
Data S1. Supporting Information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1H. Sun, P. Saeedi, S. Karuranga, et al., “IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045,” Diabetes Research and Clinical Practice 183 (2022): 109119, https://doi.org/10.1016/j.diabres.2021.109119.
- 2M. Bergman, M. Manco, I. Satman, et al., “International Diabetes Federation Position Statement on the 1-Hour Post-Load Plasma Glucose for the Diagnosis of Intermediate Hyperglycaemia and Type 2 Diabetes,” Diabetes Research and Clinical Practice 209 (2024): 111589, https://doi.org/10.1016/j.diabres.2024.111589.
- 3M. C. Thomas, M. Brownlee, K. Susztak, et al., “Diabetic Kidney Disease,” Nature Reviews Disease Primers 1, no. 1 (2015): 15018, https://doi.org/10.1038/nrdp.2015.18.
- 4J. Chen, Q. Zhang, J. Guo, et al., “Single-Cell Transcriptomics Reveals the Ameliorative Effect of Rosmarinic Acid on Diabetic Nephropathy-Induced Kidney Injury by Modulating Oxidative Stress and Inflammation,” Acta Pharmaceutica Sinica B 14, no. 4 (2024): 1661–1676, https://doi.org/10.1016/j.apsb.2024.01.003.
- 5D. Zhong, J. Chen, R. Qiao, et al., “Genetic or Pharmacologic Blockade of mPGES-2 Attenuates Renal Lipotoxicity and Diabetic Kidney Disease by Targeting Rev-Erbα/FABP5 Signaling,” Cell Reports 43, no. 4 (2024): 114075, https://doi.org/10.1016/j.celrep.2024.114075.
- 6X. Zhang, Z. Huo, X. Jia, et al., “(+)-catechin Ameliorates Diabetic Nephropathy Injury by Inhibiting Endoplasmic Reticulum Stress-Related NLRP3-Mediated Inflammation,” Food & Function 15 (2024): 5450–5465, https://doi.org/10.1039/d3fo05400d.
- 7S. Thipsawat, “Early Detection of Diabetic Nephropathy in Patient With Type 2 Diabetes Mellitus: A Review of the Literature,” Diabetes & Vascular Disease Research 18, no. 6 (2021): 14791641211058856, https://doi.org/10.1177/14791641211058856.
- 8M. Akhtar, N. M. Taha, A. Nauman, I. B. Mujeeb, and A. D. M. H. al-Nabet, “Diabetic Kidney Disease Past and Present,” Advances in Anatomic Pathology 27, no. 2 (2020): 87–97, https://doi.org/10.1097/PAP.0000000000000257.
- 9Z. Ling, X. Liu, Y. Cheng, X. Yan, and S. Wu, “Gut Microbiota and Aging,” Critical Reviews in Food Science and Nutrition 62, no. 13 (2020): 3509–3534, https://doi.org/10.1080/10408398.2020.1867054.
- 10T. M. Cook and V. Mansuy-Aubert, “Communication Between the Gut Microbiota and Peripheral Nervous System in Health and Chronic Disease,” Gut Microbes 14, no. 1 (2022): 2068365, https://doi.org/10.1080/19490976.2022.2068365.
- 11W.-F. Zuo, Q. Pang, L.-P. Yao, et al., “Gut Microbiota: A Magical Multifunctional Target Regulated by Medicine Food Homology Species,” Journal of Advanced Research 52 (2023): 151–170, https://doi.org/10.1016/j.jare.2023.05.011.
- 12L. Yishu, D. Nan, and Z. Tianjiao, “Research Progress on the Mechanism of Danhong Injection in Promoting Blood Circulation and Removing Blood Stasis and Its Interaction with Commonly Used Anticoagulants,” Shanghai Journal of Traditional Chinese Medicine 57, no. 10 (2023): 68–75, https://doi.org/10.16305/j.1007-1334.2023.2212068.
10.16305/j.1007?1334.2023.2212068 Google Scholar
- 13L. Balint, C. Socaciu, A. I. Socaciu, et al., “Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients,” Biomolecules 13, no. 7 (2023): 1086, https://doi.org/10.3390/biom13071086.
- 14W. Yu, J. Shang, R. Guo, et al., “The Gut Microbiome in Differential Diagnosis of Diabetic Kidney Disease and Membranous Nephropathy,” Renal Failure 42, no. 1 (2020): 1100–1110, https://doi.org/10.1080/0886022x.2020.1837869.
- 15C. Zhong, Z. Dai, L. Chai, et al., “The Change of Gut Microbiota-Derived Short-Chain Fatty Acids in Diabetic Kidney Disease,” Journal of Clinical Laboratory Analysis 35, no. 12 (2021): e24062, https://doi.org/10.1002/jcla.24062.
- 16J. E. Kim, H. Nam, J. Park, et al., “Gut Microbial Genes and Metabolism for Methionine and Branched-Chain Amino Acids in Diabetic Nephropathy,” Microbiology Spectrum 11, no. 2 (2023): e02344-22, https://doi.org/10.1128/spectrum.02344-22.
- 17M. Arumugam, J. Raes, E. Pelletier, et al., “Enterotypes of the Human Gut Microbiome,” Nature 473, no. 7346 (2011): 174–180, https://doi.org/10.1038/nature09944.
- 18X. Su, W. Yu, A. Liu, et al., “San-Huang-Yi-Shen Capsule Ameliorates Diabetic Nephropathy in Rats Through Modulating the Gut Microbiota and Overall Metabolism,” Frontiers in Pharmacology 12 (2022): 808867, https://doi.org/10.3389/fphar.2021.808867.
- 19K. Jaye, C. G. Li, D. Chang, and D. J. Bhuyan, “The Role of Key Gut Microbial Metabolites in the Development and Treatment of Cancer,” Gut Microbes 14, no. 1 (2022): 2038865, https://doi.org/10.1080/19490976.2022.2038865.
- 20W. Yan, Y. Ge, L. Wang, Y. Wang, and D. He, “Causal Relationship of Gut Microbiota With Diabetic Nephropathy: A Mendelian Randomization Analysis,” Frontiers in Microbiology 14 (2024): 1281361, https://doi.org/10.3389/fmicb.2023.1281361.
- 21X. Lu, J. Ma, and R. Li, “Alterations of Gut Microbiota in Biopsy-Proven Diabetic Nephropathy and a Long History of Diabetes Without Kidney Damage,” Scientific Reports 13, no. 1 (2023): 12150, https://doi.org/10.1038/s41598-023-39444-4.
- 22L. Zhang, L. Qi-Yu, W. Hao, C. Yan-Li, K. Jing, and X. Zhong-Gao, “The Intestinal Microbiota Composition in Early and Late Stages of Diabetic Kidney Disease,” Microbiology Spectrum 11, no. 4 (2023): e0038223, https://doi.org/10.1128/spectrum.00382-23.
- 23W. Chen, M. Zhang, Y. Guo, et al., “The Profile and Function of Gut Microbiota in Diabetic Nephropathy,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 14 (2021): 4283–4296, https://doi.org/10.2147/dmso.S320169.
- 24X. Du, J. Liu, Y. Xue, et al., “Alteration of Gut Microbial Profile in Patients With Diabetic Nephropathy,” Endocrine 73, no. 1 (2021): 71–84, https://doi.org/10.1007/s12020-021-02721-1.
- 25Q. Yang, L. Deng, C. Feng, and J. Wen, “Comparing the Effects of Empagliflozin and Liraglutide on Lipid Metabolism and Intestinal Microflora in Diabetic Mice,” PeerJ 12 (2024): e17055, https://doi.org/10.7717/peerj.17055.
- 26Y. Jin, C. Han, D. Yang, and S. Gao, “Association Between Gut Microbiota and Diabetic Nephropathy: A Mendelian Randomization Study,” Frontiers in Microbiology 15 (2024): 1309871, https://doi.org/10.3389/fmicb.2024.1309871.
- 27Y. Fang, Y. Zhang, Q. Liu, Z. Zheng, C. Ren, and X. Zhang, “Assessing the Causal Relationship Between Gut Microbiota and Diabetic Nephropathy: Insights From Two-Sample Mendelian Randomization,” Frontiers in Endocrinology 15 (2024): 1329954, https://doi.org/10.3389/fendo.2024.1329954.
- 28X. Lu, J. Ma, L. Guo, W. Wu, and R. Li, “Associations of Genetic Variants Contributing to Gut Microbiota Composition in Diabetic Nephropathy,” Frontiers in Endocrinology 14 (2023): 1264517, https://doi.org/10.3389/fendo.2023.1264517.
- 29X. He, J. Sun, C. Liu, et al., “Compositional Alterations of Gut Microbiota in Patients With Diabetic Kidney Disease and Type 2 Diabetes Mellitus,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 15 (2022): 755–765, https://doi.org/10.2147/dmso.S347805.
- 30L. Zhang, Z. Wang, X. Zhang, et al., “Alterations of the Gut Microbiota in Patients With Diabetic Nephropathy,” Microbiology Spectrum 10, no. 4 (2022): 1–16, https://doi.org/10.1128/spectrum.00324-22.
- 31X. Lyu, T. Zhang, Z. Ye, and C. Chen, “Astragaloside IV Mitigated Diabetic Nephropathy by Restructuring Intestinal Microflora and Ferroptosis,” Molecular Nutrition & Food Research 68, no. 6 (2024): 2300734, https://doi.org/10.1002/mnfr.202300734.
- 32P. Wang, R. Guo, X. Bai, et al., “Sacubitril/Valsartan Contributes to Improving the Diabetic Kidney Disease and Regulating the Gut Microbiota in Mice,” Frontiers in Endocrinology 13 (2022): 1034818, https://doi.org/10.3389/fendo.2022.1034818.
- 33Q. Chen, D. Ren, J. Wu, et al., “Shenyan Kangfu Tablet Alleviates Diabetic Kidney Disease Through Attenuating Inflammation and Modulating the Gut Microbiota,” Journal of Natural Medicines 75, no. 1 (2020): 84–98, https://doi.org/10.1007/s11418-020-01452-3.
- 34F. Wang, C. Liu, L. Ren, et al., “Sanziguben Polysaccharides Improve Diabetic Nephropathy in Mice by Regulating Gut Microbiota to Inhibit the TLR4/NF-κB/NLRP3 Signalling Pathway,” Pharmaceutical Biology 61, no. 1 (2023): 427–436, https://doi.org/10.1080/13880209.2023.2174145.
- 35K. Cai, Y. Ma, F. Cai, et al., “Changes of Gut Microbiota in Diabetic Nephropathy and Its Effect on the Progression of Kidney Injury,” Endocrine 76, no. 2 (2022): 294–303, https://doi.org/10.1007/s12020-022-03002-1.
- 36J. Shang, W. Cui, R. Guo, et al., “The Harmful Intestinal Microbial Community Accumulates During DKD Exacerbation and Microbiome–Metabolome Combined Validation in a Mouse Model,” Frontiers in Endocrinology 13 (2022): 964389, https://doi.org/10.3389/fendo.2022.964389.
- 37J. Wu, Y. Chen, H. Yang, et al., “Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition via Dapagliflozin Improves Diabetic Kidney Disease (DKD) Over Time Associatied With Increasing Effect on the Gut Microbiota in Db/Db Mice,” Frontiers in Endocrinology 14 (2023): 1026040, https://doi.org/10.3389/fendo.2023.1026040.
- 38Z. Zhang, Q. Li, F. Liu, and D. Wang, “Lycoperoside H Protects Against Diabetic Nephropathy via Alteration of Gut Microbiota and Inflammation,” Journal of Biochemical and Molecular Toxicology 36, no. 12 (2022): e23216, https://doi.org/10.1002/jbt.23216.
- 39J. Hong, T. Fu, W. Liu, et al., “Specific Alternation of Gut Microbiota and the Role of Ruminococcus gnavus in the Development of Diabetic Nephropathy,” Journal of Microbiology and Biotechnology 34, no. 3 (2023): 547–561, https://doi.org/10.4014/jmb.2310.10028.
- 40W. Dong, Y. Zhao, X. Li, J. Huo, and W. Wang, “Corn Silk Polysaccharides Attenuate Diabetic Nephropathy Through Restoration of the Gut Microbial Ecosystem and Metabolic Homeostasis,” Frontiers in Endocrinology 14 (2023): 1232132, https://doi.org/10.3389/fendo.2023.1232132.
- 41C. Han, Z. Shen, T. Cui, et al., “Yi-Shen-Hua-Shi Granule Ameliorates Diabetic Kidney Disease by the “Gut-Kidney Axis”,” Journal of Ethnopharmacology 307 (2023): 116257, https://doi.org/10.1016/j.jep.2023.116257.
- 42T.-T. Cai, X.-L. Ye, R.-R. Li, et al., “Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice,” Frontiers in Pharmacology 11 (2020): 1249, https://doi.org/10.3389/fphar.2020.01249.
- 43S. Tao, L. Li, L. Li, et al., “Understanding the Gut–Kidney Axis Among Biopsy-Proven Diabetic Nephropathy, Type 2 Diabetes Mellitus and Healthy Controls: An Analysis of the Gut Microbiota Composition,” Acta Diabetologica 56, no. 5 (2019): 581–592, https://doi.org/10.1007/s00592-019-01316-7.
- 44S. Yan, H. Wang, B. Feng, L. Ye, and A. Chen, “Causal Relationship Between Gut Microbiota and Diabetic Nephropathy: A Two-Sample Mendelian Randomization Study,” Frontiers in Immunology 15 (2024): 1332757, https://doi.org/10.3389/fimmu.2024.1332757.
- 45A. Wahlström, I. Sayin Sama, H.-U. Marschall, S. . I. Sayin, and F. Bäckhed, “Intestinal Crosstalk Between Bile Acids and Microbiota and Its Impact on Host Metabolism,” Cell Metabolism 24, no. 1 (2016): 41–50, https://doi.org/10.1016/j.cmet.2016.05.005.
- 46T. Q. de Aguiar Vallim, E. J. Tarling, and P. A. Edwards, “Pleiotropic Roles of Bile Acids in Metabolism,” Cell Metabolism 17, no. 5 (2013): 657–669, https://doi.org/10.1016/j.cmet.2013.03.013.
- 47J. Li, J.-l. Lv, X.-y. Cao, et al., “Gut Microbiota Dysbiosis as an Inflammaging Condition That Regulates Obesity-Related Retinopathy and Nephropathy,” Frontiers in Microbiology 13 (2022): 1040846, https://doi.org/10.3389/fmicb.2022.1040846.
- 48E. Castillo-Rodriguez, R. Fernandez-Prado, R. Esteras, et al., “Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression,” Toxins 10, no. 7 (2018): 300, https://doi.org/10.3390/toxins10070300.
- 49E. M. Onal, B. Afsar, A. Covic, N. D. Vaziri, and M. Kanbay, “Gut Microbiota and Inflammation in Chronic Kidney Disease and Their Roles in the Development of Cardiovascular Disease,” Hypertension Research 42, no. 2 (2018): 123–140, https://doi.org/10.1038/s41440-018-0144-z.
- 50T. Zhao, H. Zhang, X. Yin, et al., “Tangshen Formula Modulates Gut Microbiota and Reduces Gut-Derived Toxins in Diabetic Nephropathy Rats,” Biomedicine & Pharmacotherapy 129 (2020): 110325, https://doi.org/10.1016/j.biopha.2020.110325.
- 51W. Huang, Y. Man, C. Gao, et al., “Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κB Signaling,” Oxidative Medicine and Cellular Longevity 2020 (2020): 1–21, https://doi.org/10.1155/2020/4074832.
10.1155/2020/8706898 Google Scholar
- 52Q. Fang, N. Liu, B. Zheng, et al., “Roles of Gut Microbial Metabolites in Diabetic Kidney Disease,” Frontiers in Endocrinology 12 (2021): 636175, https://doi.org/10.3389/fendo.2021.636175.
- 53M. Sylvestre, S. E. Di Carlo, and L. Peduto, “Stromal Regulation of the Intestinal Barrier,” Mucosal Immunology 16, no. 2 (2023): 221–231, https://doi.org/10.1016/j.mucimm.2023.01.006.
- 54Y. Cui, Q. Wang, R. Chang, X. Zhou, and C. Xu, “Intestinal Barrier Function–Non-Alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota,” Journal of Agricultural and Food Chemistry 67, no. 10 (2019): 2754–2762, https://doi.org/10.1021/acs.jafc.9b00080.
- 55T. Zhou, Y. Zhang, Z. Li, C. Lu, and H. Zhao, “Research Progress of Traditional Chinese Medicine on the Treatment of Diarrhea by Regulating Intestinal Microbiota and Its Metabolites Based on Renal-Intestinal Axis,” Frontiers in Cellular and Infection Microbiology 14 (2024): 1483550, https://doi.org/10.3389/fcimb.2024.1483550.
- 56J. C. Nascimento, V. A. Matheus, R. B. Oliveira, S. F. S. Tada, and C. B. Collares-Buzato, “High-Fat Diet Induces Disruption of the Tight Junction-Mediated Paracellular Barrier in the Proximal Small Intestine Before the Onset of Type 2 Diabetes and Endotoxemia,” Digestive Diseases and Sciences 66, no. 10 (2020): 3359–3374, https://doi.org/10.1007/s10620-020-06664-x.
- 57W. L. Lau, J. Savoj, M. B. Nakata, W. . L. Lau, M. . B. Nakata, and N. . D. Vaziri, “Altered Microbiome in Chronic Kidney Disease: Systemic Effects of Gut-Derived Uremic Toxins,” Clinical Science 132, no. 5 (2018): 509–522, https://doi.org/10.1042/cs20171107.
- 58N. D. Vaziri, J. Yuan, A. Rahimi, Z. Ni, H. Said, and V. S. Subramanian, “Disintegration of Colonic Epithelial Tight Junction in Uremia: A Likely Cause of CKD-Associated Inflammation,” Nephrology, Dialysis, Transplantation 27, no. 7 (2012): 2686–2693, https://doi.org/10.1093/ndt/gfr624.
- 59N. D. Vaziri, J. Yuan, S. Nazertehrani, Z. Ni, and S. Liu, “Chronic Kidney Disease Causes Disruption of Gastric and Small Intestinal Epithelial Tight Junction,” American Journal of Nephrology 38, no. 2 (2013): 99–103, https://doi.org/10.1159/000353764.
- 60N. D. Vaziri, N. Goshtasbi, J. Yuan, et al., “Uremic Plasma Impairs Barrier Function and Depletes the Tight Junction Protein Constituents of Intestinal Epithelium,” American Journal of Nephrology 36, no. 5 (2012): 438–443, https://doi.org/10.1159/000343886.
- 61F. Di Vincenzo, A. Del Gaudio, V. Petito, et al., “Gut Microbiota, Intestinal Permeability, and Systemic Inflammation: A Narrative Review,” Internal and Emergency Medicine 19, no. 2 (2023): 275–293, https://doi.org/10.1007/s11739-023-03374-w.
- 62K. Kajiwara, Y. Sawa, T. Fujita, and S. Tamaoki, “Immunohistochemical Study for the Expression of Leukocyte Adhesion Molecules, and FGF23 and ACE2 in P. gingivalis LPS-Induced Diabetic Nephropathy,” BMC Nephrology 22, no. 1 (2021): 3, https://doi.org/10.1186/s12882-020-02203-y.
- 63J. Wada and H. Makino, “Innate Immunity in Diabetes and Diabetic Nephropathy,” Nature Reviews Nephrology 12, no. 1 (2015): 13–26, https://doi.org/10.1038/nrneph.2015.175.
- 64S.-M. Kim, S.-H. Lee, Y.-G. Kim, et al., “Hyperuricemia-Induced NLRP3 Activation of Macrophages Contributes to the Progression of Diabetic Nephropathy,” American Journal of Physiology. Renal Physiology 308, no. 9 (2015): F993–F1003, https://doi.org/10.1152/ajprenal.00637.2014.
- 65A. Ciesielska, M. Matyjek, and K. Kwiatkowska, “TLR4 and CD14 Trafficking and Its Influence on LPS-Induced Pro-Inflammatory Signaling,” Cellular and Molecular Life Sciences 78, no. 4 (2020): 1233–1261, https://doi.org/10.1007/s00018-020-03656-y.
- 66Q. Lv, Z. Li, A. Sui, X. Yang, Y. Han, and R. Yao, “The Role and Mechanisms of Gut Microbiota in Diabetic Nephropathy, Diabetic Retinopathy and Cardiovascular Diseases,” Frontiers in Microbiology 13 (2022): 977187, https://doi.org/10.3389/fmicb.2022.977187.
- 67B. Xiong, M. Liu, C. Zhang, et al., “Alginate Oligosaccharides Enhance Small Intestine Cell Integrity and Migration Ability,” Life Sciences 258 (2020): 118085, https://doi.org/10.1016/j.lfs.2020.118085.
- 68J. Ye, H. Dai, Y. Liu, B. Yu, J. Yang, and A. Fei, “Blockade of C3a/C3aR Axis Alleviates Severe Acute Pancreatitis-Induced Intestinal Barrier Injury,” American Journal of Translational Research 12, no. 10 (2020): 6290–6301.
- 69E. Ritz, “Intestinal-Renal Syndrome: Mirage or Reality?,” Blood Purification 31, no. 1–3 (2011): 70–76, https://doi.org/10.1159/000321848.
- 70R. Di Paola, A. De, R. Izhar, et al., “Possible Effects of Uremic Toxins p-Cresol, Indoxyl Sulfate, p-Cresyl Sulfate on the Development and Progression of Colon Cancer in Patients With Chronic Renal Failure,” Genes 14, no. 6 (2023): 1257, https://doi.org/10.3390/genes14061257.
- 71J. Lei, Y. Xie, J. Sheng, and J. Song, “Intestinal Microbiota Dysbiosis in Acute Kidney Injury: Novel Insights Into Mechanisms and Promising Therapeutic Strategies,” Renal Failure 44, no. 1 (2022): 571–580, https://doi.org/10.1080/0886022x.2022.2056054.
- 72S. Han, M. Chen, P. Cheng, et al., “A Systematic Review and Meta-Analysis of Gut Microbiota in Diabetic Kidney Disease: Comparisons With Diabetes Mellitus, Non-Diabetic Kidney Disease, and Healthy Individuals,” Frontiers in Endocrinology 13 (2022): 1018093, https://doi.org/10.3389/fendo.2022.1018093.
- 73M. V. Ristori, A. Quagliariello, S. Reddel, et al., “Autism, Gastrointestinal Symptoms and Modulation of Gut Microbiota by Nutritional Interventions,” Nutrients 11, no. 11 (2019): 2812, https://doi.org/10.3390/nu11112812.
- 74A. Rydzewska-Rosołowska, N. Sroka, K. Kakareko, M. Rosołowski, E. Zbroch, and T. Hryszko, “The Links Between Microbiome and Uremic Toxins in Acute Kidney Injury: Beyond Gut Feeling—A Systematic Review,” Toxins 12, no. 12 (2020): 788, https://doi.org/10.3390/toxins12120788.
- 75R. J. F. Felizardo, I. K. M. Watanabe, P. Dardi, L. V. Rossoni, and N. O. S. Câmara, “The Interplay Among Gut Microbiota, Hypertension and Kidney Diseases: The Role of Short-Chain Fatty Acids,” Pharmacological Research 141 (2019): 366–377, https://doi.org/10.1016/j.phrs.2019.01.019.
- 76K. Taguchi, K. Fukami, B. C. Elias, and C. R. Brooks, “Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease,” Toxins 13, no. 5 (2021): 361, https://doi.org/10.3390/toxins13050361.
- 77G. Caggiano, A. Stasi, R. Franzin, et al., “Fecal Microbiota Transplantation in Reducing Uremic Toxins Accumulation in Kidney Disease: Current Understanding and Future Perspectives,” Toxins 15, no. 2 (2023): 115, https://doi.org/10.3390/toxins15020115.
- 78N. G. Vallianou, D. Kounatidis, F. Panagopoulos, et al., “Gut Microbiota and Its Role in the Brain-Gut-Kidney Axis in Hypertension,” Current Hypertension Reports 25, no. 11 (2023): 367–376, https://doi.org/10.1007/s11906-023-01263-3.
- 79L. Giordano, S. M. Mihaila, H. Eslami Amirabadi, and R. Masereeuw, “Microphysiological Systems to Recapitulate the Gut–Kidney Axis,” Trends in Biotechnology 39, no. 8 (2021): 811–823, https://doi.org/10.1016/j.tibtech.2020.12.001.
- 80F. Mahmoodpoor, Y. Rahbar Saadat, A. Barzegari, M. Ardalan, and S. Zununi Vahed, “The Impact of Gut Microbiota on Kidney Function and Pathogenesis,” Biomedicine & Pharmacotherapy 93 (2017): 412–419, https://doi.org/10.1016/j.biopha.2017.06.066.
- 81J. Rysz, B. Franczyk, J. Ławiński, R. Olszewski, A. Ciałkowska-Rysz, and A. Gluba-Brzózka, “The Impact of CKD on Uremic Toxins and Gut Microbiota,” Toxins 13, no. 4 (2021): 252, https://doi.org/10.3390/toxins13040252.
- 82T. Lan, T. Tang, Y. Li, et al., “FTZ Polysaccharides Ameliorate Kidney Injury in Diabetic Mice by Regulating Gut-Kidney Axis,” Phytomedicine 118 (2023): 154935, https://doi.org/10.1016/j.phymed.2023.154935.
- 83H.-W. Huang and M.-J. Chen, “Exploring the Preventive and Therapeutic Mechanisms of Probiotics in Chronic Kidney Disease Through the Gut–Kidney Axis,” Journal of Agricultural and Food Chemistry 72, no. 15 (2024): 8347–8364, https://doi.org/10.1021/acs.jafc.4c00263.
- 84E. Choi, J. Yang, G.-E. Ji, et al., “The Effect of Probiotic Supplementation on Systemic Inflammation in Dialysis Patients,” Kidney Research and Clinical Practice 41, no. 1 (2022): 89–101, https://doi.org/10.23876/j.krcp.21.014.
- 85Z. Shen, T. Cui, Y. Liu, S. Wu, C. Han, and J. Li, “Astragalus Membranaceus and Salvia miltiorrhiza Ameliorate Diabetic Kidney Disease via the “Gut-Kidney Axis”,” Phytomedicine 121 (2023): 155129, https://doi.org/10.1016/j.phymed.2023.155129.
- 86M. Ha, Y. Yang, M. Wu, T. Gong, Z. Chen, and L. Yu, “Astaxanthin Could Regulate the Gut-Kidney Axis to Mitigate Kidney Injury in High-Fat Diet/Streptozotocin-Induced Diabetic Mice,” International Journal for Vitamin and Nutrition Research 94, no. 3-4 (2024): 187–197, https://doi.org/10.1024/0300-9831/a000786.
- 87A. Koh, F. De Vadder, P. Kovatcheva-Datchary, et al., “From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites,” Cell 165, no. 6 (2016): 1332–1345, https://doi.org/10.1016/j.cell.2016.05.041.
- 88T. Hu, Q. Wu, Q. Yao, K. Jiang, J. Yu, and Q. Tang, “Short-Chain Fatty Acid Metabolism and Multiple Effects on Cardiovascular Diseases,” Ageing Research Reviews 81 (2022): 101706, https://doi.org/10.1016/j.arr.2022.101706.
- 89T. Ikeda, A. Nishida, M. Yamano, and I. Kimura, “Short-Chain Fatty Acid Receptors and Gut Microbiota as Therapeutic Targets in Metabolic, Immune, and Neurological Diseases,” Pharmacology & Therapeutics 239 (2022): 108273, https://doi.org/10.1016/j.pharmthera.2022.108273.
- 90M. A. R. Vinolo, H. G. Rodrigues, R. T. Nachbar, and R. Curi, “Regulation of Inflammation by Short Chain Fatty Acids,” Nutrients 3, no. 10 (2011): 858–876, https://doi.org/10.3390/nu3100858.
- 91Y. J. Li, X. Chen, T. K. Kwan, et al., “Dietary Fiber Protects Against Diabetic Nephropathy Through Short-Chain Fatty Acid–Mediated Activation of G Protein–Coupled Receptors GPR43 and GPR109A,” Journal of the American Society of Nephrology 31, no. 6 (2020): 1267–1281, https://doi.org/10.1681/asn.2019101029.
- 92T. Zhou, H. Xu, X. Cheng, et al., “Sodium Butyrate Attenuates Diabetic Kidney Disease Partially via Histone Butyrylation Modification,” Mediators of Inflammation 2022 (2022): 1–16, https://doi.org/10.1155/2022/7643322.
- 93M. H. Kim, S. G. Kang, J. H. Park, M. Yanagisawa, and C. H. Kim, “Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice,” Gastroenterology 145, no. 2 (2013): 396–406.e10, https://doi.org/10.1053/j.gastro.2013.04.056.
- 94Y. J. Lim, N. A. Sidor, N. C. Tonial, A. Che, and B. L. Urquhart, “Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets,” Toxins 13, no. 2 (2021): 142, https://doi.org/10.3390/toxins13020142.
- 95A. B. Shreiner, J. Y. Kao, and V. B. Young, “The Gut Microbiome in Health and in Disease,” Current Opinion in Gastroenterology 31, no. 1 (2015): 69–75, https://doi.org/10.1097/mog.0000000000000139.
- 96Z. Wang, E. Klipfell, B. J. Bennett, et al., “Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease,” Nature 472, no. 7341 (2011): 57–63, https://doi.org/10.1038/nature09922.
- 97C. E. Cho, S. Taesuwan, O. V. Malysheva, et al., “Trimethylamine-N-Oxide (TMAO) Response to Animal Source Foods Varies Among Healthy Young Men and Is Influenced by Their Gut Microbiota Composition: A Randomized Controlled Trial,” Molecular Nutrition & Food Research 61, no. 1 (2016): 1600324, https://doi.org/10.1002/mnfr.201600324.
10.1002/mnfr.201600324 Google Scholar
- 98C. E. Cho and M. A. Caudill, “Trimethylamine- N -Oxide: Friend, Foe, or Simply Caught in the Cross-Fire?,” Trends in Endocrinology and Metabolism 28, no. 2 (2017): 121–130, https://doi.org/10.1016/j.tem.2016.10.005.
- 99X. Zhang, Y. Li, P. Yang, et al., “Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals,” Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 3 (2020): 751–765, https://doi.org/10.1161/atvbaha.119.313414.
- 100D. Schneditz, X. Hai, V. Landeras, et al., “Mechanism of Prominent Trimethylamine Oxide (TMAO) Accumulation in Hemodialysis Patients,” PLoS One 10, no. 12 (2015): e0143731, https://doi.org/10.1371/journal.pone.0143731.
- 101N. Yu, N. Gu, Y. Wang, et al., “The Association of Plasma Trimethylamine N-Oxide With Coronary Atherosclerotic Burden in Patients With Type 2 Diabetes Among a Chinese North Population,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 15 (2022): 69–78, https://doi.org/10.2147/dmso.S339698.
- 102E. G. Gruppen, E. Garcia, M. A. Connelly, et al., “TMAO Is Associated With Mortality: Impact of Modestly Impaired Renal Function,” Scientific Reports 7, no. 1 (2017): 13781, https://doi.org/10.1038/s41598-017-13739-9.
- 103J. Geng, C. Yang, B. Wang, et al., “Trimethylamine N-Oxide Promotes Atherosclerosis via CD36-Dependent MAPK/JNK Pathway,” Biomedicine & Pharmacotherapy 97 (2018): 941–947, https://doi.org/10.1016/j.biopha.2017.11.016.
- 104A. Mohammadi, Z. Vahabzadeh, S. Jamalzadeh, and T. Khalili, “Trimethylamine-N-Oxide, as a Risk Factor for Atherosclerosis, Induces Stress in J774A.1 Murine Macrophages,” Advances in Medical Sciences 63, no. 1 (2018): 57–63, https://doi.org/10.1016/j.advms.2017.06.006.
- 105L. Luo, W. Zhang, Z. Zhang, et al., “The Water Extract of “Jiao Mei Gu” Attenuates the Lipopolysaccharide-Induced Inflammatory Response via Inhibiting NF-κB Activity in Mice,” Journal of Ethnopharmacology 259 (2020): 112882, https://doi.org/10.1016/j.jep.2020.112882.
- 106J. W. Jang, E. Capaldi, T. Smith, P. Verma, J. Varga, and K. J. Ho, “Trimethylamine N-Oxide: A Meta-Organismal Axis Linking the Gut and Fibrosis,” Molecular Medicine 30, no. 1 (2024): 128, https://doi.org/10.1186/s10020-024-00895-8.
- 107I. Fernández-Ruiz, “Gut Microbes Modulate Platelet Function and Thrombosis Risk,” Nature Reviews Cardiology 13, no. 5 (2016): 247, https://doi.org/10.1038/nrcardio.2016.47.
- 108R. Kaur, M. Kaur, and J. Singh, “Endothelial Dysfunction and Platelet Hyperactivity in Type 2 Diabetes Mellitus: Molecular Insights and Therapeutic Strategies,” Cardiovascular Diabetology 17, no. 1 (2018): 121, https://doi.org/10.1186/s12933-018-0763-3.
- 109C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans, “Targeting Bile-Acid Signalling for Metabolic Diseases,” Nature Reviews Drug Discovery 7, no. 8 (2008): 678–693, https://doi.org/10.1038/nrd2619.
- 110J. M. Ridlon and J. S. Bajaj, “The Human Gut Sterolbiome: Bile Acid-Microbiome Endocrine Aspects and Therapeutics,” Acta Pharmaceutica Sinica B 5, no. 2 (2015): 99–105, https://doi.org/10.1016/j.apsb.2015.01.006.
- 111M. Kisiela, A. Skarka, B. Ebert, and E. Maser, “Hydroxysteroid Dehydrogenases (HSDs) in Bacteria – A Bioinformatic Perspective,” Journal of Steroid Biochemistry and Molecular Biology 129, no. 1–2 (2012): 31–46, https://doi.org/10.1016/j.jsbmb.2011.08.002.
- 112T. Geng, Q. Lu, L. Jiang, et al., “Circulating Concentrations of Bile Acids and Prevalent Chronic Kidney Disease Among Newly Diagnosed Type 2 Diabetes: A Cross-Sectional Study,” Nutrition Journal 23, no. 1 (2024): 28, https://doi.org/10.1186/s12937-024-00928-2.
- 113Z. Lin, S. Li, H. Xiao, et al., “The Degradation of TGR5 Mediated by Smurf1 Contributes to Diabetic Nephropathy,” Cell Reports 42, no. 8 (2023): 112851, https://doi.org/10.1016/j.celrep.2023.112851.
- 114A. Bertolini, R. Fiorotto, and M. Strazzabosco, “Bile Acids and Their Receptors: Modulators and Therapeutic Targets in Liver Inflammation,” Seminars in Immunopathology 44, no. 4 (2022): 547–564, https://doi.org/10.1007/s00281-022-00935-7.
- 115U. Beuers, M. Trauner, P. Jansen, and R. Poupon, “New Paradigms in the Treatment of Hepatic Cholestasis: From UDCA to FXR, PXR and Beyond,” Journal of Hepatology 62, no. 1 (2015): S25–S37, https://doi.org/10.1016/j.jhep.2015.02.023.
- 116X. X. Wang, D. Wang, Y. Luo, et al., “FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity,” Journal of the American Society of Nephrology 29, no. 1 (2018): 118–137, https://doi.org/10.1681/asn.2017020222.
- 117J. S. Teodoro, A. P. Rolo, and C. M. Palmeira, “Hepatic FXR: Key Regulator of Whole-Body Energy Metabolism,” Trends in Endocrinology and Metabolism 22, no. 11 (2011): 458–466, https://doi.org/10.1016/j.tem.2011.07.002.
- 118D.-H. Kim, J. S. Park, H.-I. Choi, et al., “The Role of the Farnesoid X Receptor in Kidney Health and Disease: A Potential Therapeutic Target in Kidney Diseases,” Experimental & Molecular Medicine 55, no. 2 (2023): 304–312, https://doi.org/10.1038/s12276-023-00932-2.
- 119X. Wang and P. J. Quinn, “Lipopolysaccharide: Biosynthetic Pathway and Structure Modification,” Progress in Lipid Research 49, no. 2 (2010): 97–107, https://doi.org/10.1016/j.plipres.2009.06.002.
- 120A. Verma, G. Azhar, X. Zhang, et al., “P. gingivalis-LPS Induces Mitochondrial Dysfunction Mediated by Neuroinflammation Through Oxidative Stress,” International Journal of Molecular Sciences 24, no. 2 (2023): 950, https://doi.org/10.3390/ijms24020950.
- 121A. M. Fonceca, G. R. Zosky, E. M. Bozanich, et al., “Accumulation Mode Particles and LPS Exposure Induce TLR-4 Dependent and Independent Inflammatory Responses in the Lung,” Respiratory Research 19, no. 1 (2018): 15, https://doi.org/10.1186/s12931-017-0701-z.
- 122K. Kajiwara and Y. Sawa, “Overexpression of SGLT2 in the Kidney of a P. gingivalis LPS-Induced Diabetic Nephropathy Mouse Model,” BMC Nephrology 22, no. 1 (2021): 287, https://doi.org/10.1186/s12882-021-02506-8.
- 123O.-Y. Kwon and S.-H. Lee, “Ishige Okamurae Attenuates Neuroinflammation and Cognitive Deficits in Mice Intracerebroventricularly Injected With LPS via Regulating TLR-4/MyD88-Dependent Pathways,” Antioxidants 12, no. 1 (2022): 78, https://doi.org/10.3390/antiox12010078.
- 124B. Zhou, Q. Li, J. Wang, P. Chen, and S. Jiang, “Ellagic Acid Attenuates Streptozocin Induced Diabetic Nephropathy via the Regulation of Oxidative Stress and Inflammatory Signaling,” Food and Chemical Toxicology 123 (2019): 16–27, https://doi.org/10.1016/j.fct.2018.10.036.
- 125X. Chen, C. Chen, and X. Fu, “Dendrobium Officinale Polysaccharide Alleviates Type 2 Diabetes Mellitus by Restoring Gut Microbiota and Repairing Intestinal Barrier via the LPS/TLR4/TRIF/NF-kB Axis,” Journal of Agricultural and Food Chemistry 71, no. 31 (2023): 11929–11940, https://doi.org/10.1021/acs.jafc.3c02429.
- 126M. J. A. Saad, A. Santos, and P. O. Prada, “Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance,” Physiology 31, no. 4 (2016): 283–293, https://doi.org/10.1152/physiol.00041.2015.
- 127P. Shen, S. Ji, X. Li, et al., “LPS-Induced Systemic Inflammation Caused mPOA-FSH/LH Disturbance and Impaired Testicular Function,” Frontiers in Endocrinology 13 (2022): 886085, https://doi.org/10.3389/fendo.2022.886085.
- 128W. Zhou, W.-h. Wu, Z.-l. Si, et al., “The Gut Microbe Bacteroides fragilis Ameliorates Renal Fibrosis in Mice,” Nature Communications 13, no. 1 (2022): 6081, https://doi.org/10.1038/s41467-022-33824-6.
- 129L. Koppe, D. Fouque, and C. O. Soulage, “Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins,” Current Diabetes Reports 18, no. 10 (2018): 97, https://doi.org/10.1007/s11892-018-1064-7.
- 130Y.-Q. Tan, Y.-N. Wang, H.-Y. Feng, et al., “Host/Microbiota Interactions-Derived Tryptophan Metabolites Modulate Oxidative Stress and Inflammation via Aryl Hydrocarbon Receptor Signaling,” Free Radical Biology and Medicine 184 (2022): 30–41, https://doi.org/10.1016/j.freeradbiomed.2022.03.025.
- 131H. Xie, N. Yang, C. Yu, and L. Lu, “Uremic Toxins Mediate Kidney Diseases: The Role of Aryl Hydrocarbon Receptor,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 38, https://doi.org/10.1186/s11658-024-00550-4.
- 132T. Nakano, S. Katsuki, M. Chen, et al., “Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation via the Interplay of OATP2B1 and Dll4-Notch Signaling,” Circulation 139, no. 1 (2019): 78–96, https://doi.org/10.1161/circulationaha.118.034588.
- 133T. Nakano, H. Watanabe, T. Imafuku, et al., “Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via the OAT/NADPH Oxidase/ROS Pathway,” Toxins 13, no. 12 (2021): 909, https://doi.org/10.3390/toxins13120909.
- 134Y. Huang, J. Zhou, S. Wang, et al., “Indoxyl Sulfate Induces Intestinal Barrier Injury Through IRF1-DRP1 Axis-Mediated Mitophagy Impairment,” Theranostics 10, no. 16 (2020): 7384–7400, https://doi.org/10.7150/thno.45455.
- 135H. Hou, M. Horikawa, Y. Narita, et al., “Suppression of Indoxyl Sulfate Accumulation Reduces Renal Fibrosis in Sulfotransferase 1a1-Deficient Mice,” International Journal of Molecular Sciences 24, no. 14 (2023): 11329, https://doi.org/10.3390/ijms241411329.
- 136K. E. Murros, “Hydrogen Sulfide Produced by Gut Bacteria May Induce Parkinson's Disease,” Cells 11, no. 6 (2022): 978, https://doi.org/10.3390/cells11060978.
- 137S. Kundu, S. B. Pushpakumar, A. Tyagi, D. Coley, and U. Sen, “Hydrogen Sulfide Deficiency and Diabetic Renal Remodeling: Role of Matrix Metalloproteinase-9,” American Journal of Physiology. Endocrinology and Metabolism 304, no. 12 (2013): E1365–E1378, https://doi.org/10.1152/ajpendo.00604.2012.
- 138Z.-Z. Xie, M.-M. Shi, L. Xie, et al., “Sulfhydration of p66Shc at Cysteine59 Mediates the Antioxidant Effect of Hydrogen Sulfide,” Antioxidants & Redox Signaling 21, no. 18 (2014): 2531–2542, https://doi.org/10.1089/ars.2013.5604.
- 139H. J. Lee, D. Y. Lee, M. M. Mariappan, et al., “Hydrogen Sulfide Inhibits High Glucose-Induced NADPH Oxidase 4 Expression and Matrix Increase by Recruiting Inducible Nitric Oxide Synthase in Kidney Proximal Tubular Epithelial Cells,” Journal of Biological Chemistry 292, no. 14 (2017): 5665–5675, https://doi.org/10.1074/jbc.M116.766758.
- 140T. Koshida, T. Gohda, T. Sugimoto, et al., “Gut Microbiome and Microbiome-Derived Metabolites in Patients With End-Stage Kidney Disease,” International Journal of Molecular Sciences 24, no. 14 (2023): 11456, https://doi.org/10.3390/ijms241411456.
- 141L. Koppe, D. Mafra, and D. Fouque, “Probiotics and Chronic Kidney Disease,” Kidney International 88, no. 5 (2015): 958–966, https://doi.org/10.1038/ki.2015.255.
- 142A. Ghosh, A. Muley, A. S. Ainapure, A. R. Deshmane, and A. Mahajan, “Exploring the Impact of Optimized Probiotic Supplementation Techniques on Diabetic Nephropathy: Mechanisms and Therapeutic Potential,” Cureus 16 (2024): e55149, https://doi.org/10.7759/cureus.55149.
- 143Y. Zhang, X. Meng, Z. Ma, Z. Sun, and Z. Wang, “Effects of Probiotic Supplementation on Nutrient Intake, Ghrelin, and Adiponectin Concentrations in Diabetic Hemodialysis Patients,” Alternative Therapies in Health and Medicine 29, no. 4 (2023): 36–42.
- 144R. Amelia, F. M. Said, F. Yasmin, H. Harun, and T. Tofrizal, “The Anti-Inflammatory Activity of Probiotic Dadiah to Activate Sirtuin-1 in Inhibiting Diabetic Nephropathy Progression,” Journal of Diabetes & Metabolic Disorders 22, no. 2 (2023): 1425–1442, https://doi.org/10.1007/s40200-023-01265-7.
- 145M. E. Sanders, D. J. Merenstein, G. Reid, G. R. Gibson, and R. A. Rastall, “Probiotics and Prebiotics in Intestinal Health and Disease: From Biology to the Clinic,” Nature Reviews Gastroenterology & Hepatology 16, no. 10 (2019): 605–616, https://doi.org/10.1038/s41575-019-0173-3.
- 146S. Roy, SD, “Role of Prebiotics, Probiotics, and Synbiotics in Management of Inflammatory Bowel Disease: Current Perspectives,” World Journal of Gastroenterology 29, no. 14 (2023): 2078–2100, https://doi.org/10.3748/wjg.v29.i14.2078.
- 147F. M. D. Husmann, M. B. Zimmermann, and I. Herter-Aeberli, “The Effect of Prebiotics on Human Iron Absorption: A Review,” Advances in Nutrition 13, no. 6 (2022): 2296–2304, https://doi.org/10.1093/advances/nmac079.
- 148N. Pengrattanachot, L. Thongnak, and A. Lungkaphin, “The Impact of Prebiotic Fructooligosaccharides on Gut Dysbiosis and Inflammation in Obesity and Diabetes Related Kidney Disease,” Food & Function 13, no. 11 (2022): 5925–5945, https://doi.org/10.1039/d1fo04428a.
- 149S. Liu, L. Wang, Z. Zhang, et al., “The Potential of Astragalus Polysaccharide for Treating Diabetes and Its Action Mechanism,” Frontiers in Pharmacology 15 (2024): 1339406, https://doi.org/10.3389/fphar.2024.1339406.
- 150F. Ghavidel, H. Amiri, M. H. Tabrizi, S. Alidadi, H. Hosseini, and A. Sahebkar, “The Combinational Effect of Inulin and Resveratrol on the Oxidative Stress and Inflammation Level in a Rat Model of Diabetic Nephropathy,” Current Developments in Nutrition 8, no. 1 (2024): 102059, https://doi.org/10.1016/j.cdnut.2023.102059.
- 151Z. Zhong, Y. Zhang, Y. Wei, et al., “Fucoidan Improves Early Stage Diabetic Nephropathy via the Gut Microbiota–Mitochondria Axis in High-Fat Diet-Induced Diabetic Mice,” Journal of Agricultural and Food Chemistry 72, no. 17 (2024): 9755–9767, https://doi.org/10.1021/acs.jafc.3c08503.
- 152R. Zheng, Q. Xu, Y. Wang, Y. Zhong, and R. Zhu, “Cordyceps Cicadae Polysaccharides Attenuate Diabetic Nephropathy via the miR-30a-3p/TRIM16 Axis,” Journal of Diabetes Investigation 15, no. 3 (2023): 300–314, https://doi.org/10.1111/jdi.14116.
- 153M. Ding, Z. Tang, W. Liu, et al., “Burdock Fructooligosaccharide Attenuates High Glucose-Induced Apoptosis and Oxidative Stress Injury in Renal Tubular Epithelial Cells,” Frontiers in Pharmacology 12 (2021): 784187, https://doi.org/10.3389/fphar.2021.784187.
- 154L. Wu, X. Zhang, J. Zhao, M. Yang, J. Yang, and P. Qiu, “The Therapeutic Effects of Marine Sulfated Polysaccharides on Diabetic Nephropathy,” International Journal of Biological Macromolecules 261 (2024): 129269, https://doi.org/10.1016/j.ijbiomac.2024.129269.
- 155C. Favero, L. Giordano, S. M. Mihaila, R. Masereeuw, A. Ortiz, and M. D. Sanchez-Niño, “Postbiotics and Kidney Disease,” Toxins 14, no. 9 (2022): 623, https://doi.org/10.3390/toxins14090623.
- 156A. Zepeda-Hernández, L. E. Garcia-Amezquita, T. Requena, and T. García-Cayuela, “Probiotics, Prebiotics, and Synbiotics Added to Dairy Products: Uses and Applications to Manage Type 2 Diabetes,” Food Research International 142 (2021): 110208, https://doi.org/10.1016/j.foodres.2021.110208.
- 157I. Baroni, D. Fabrizi, M. Luciani, et al., “Probiotics and Synbiotics for Glycemic Control in Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,” Clinical Nutrition 43, no. 4 (2024): 1041–1061, https://doi.org/10.1016/j.clnu.2024.03.006.
- 158A. Jayedi, A. Aletaha, S. Zeraattalab-Motlagh, et al., “Comparative Efficacy and Safety of Probiotics, Prebiotics, and Synbiotics for Type 2 Diabetes Management: A Systematic Review and Network Meta-Analysis,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews 18, no. 1 (2024): 102923, https://doi.org/10.1016/j.dsx.2023.102923.
- 159O. H. Kavita, U. Chand, H. Om, and P. K. Kushawaha, “Postbiotics: An Alternative and Innovative Intervention for the Therapy of Inflammatory Bowel Disease,” Microbiological Research 279 (2024): 127550, https://doi.org/10.1016/j.micres.2023.127550.
- 160S. Gurunathan, P. Thangaraj, and J.-H. Kim, “Postbiotics: Functional Food Materials and Therapeutic Agents for Cancer, Diabetes, and Inflammatory Diseases,” Food 13, no. 1 (2023): 89, https://doi.org/10.3390/foods13010089.
- 161Q. Chen, X.-J. Li, W. Xie, Z.-A. Su, G.-M. Qin, and C.-H. Yu, “Postbiotics: Emerging Therapeutic Approach in Diabetic Retinopathy,” Frontiers in Microbiology 15 (2024): 1359949, https://doi.org/10.3389/fmicb.2024.1359949.
- 162T.-C. Xu, Y. Liu, Z. Yu, and B. Xu, “Gut-Targeted Therapies for Type 2 Diabetes Mellitus: A Review,” World Journal of Clinical Cases 12, no. 1 (2024): 1–8, https://doi.org/10.12998/wjcc.v12.i1.1.
- 163J. H. Kim, W. Kwak, Y. Nam, et al., “Effect of Postbiotic Lactiplantibacillus Plantarum LRCC5314 Supplemented in Powdered Milk on Type 2 Diabetes in Mice,” Journal of Dairy Science 107 (2024): 5301–5315, https://doi.org/10.3168/jds.2023-24103.
- 164C. Anbalagan, S. K. Nandabalan, P. Sankar, et al., “Postbiotics of Naturally Fermented Synbiotic Mixture of Rice Water Aids in Promoting Colonocyte Health,” Biomolecules 14, no. 3 (2024): 30344, https://doi.org/10.3390/biom14030344.
- 165S. Porcari, N. Benech, M. Valles-Colomer, et al., “Key Determinants of Success in Fecal Microbiota Transplantation: From Microbiome to Clinic,” Cell Host & Microbe 31, no. 5 (2023): 712–733, https://doi.org/10.1016/j.chom.2023.03.020.
- 166P. P. Chen, J. X. Zhang, X. Q. Li, et al., “Outer Membrane Vesicles Derived From Gut Microbiota Mediate Tubulointerstitial Inflammation: A Potential New Mechanism for Diabetic Kidney Disease,” Theranostics 13, no. 12 (2023): 3988–4003, https://doi.org/10.7150/thno.84650.
- 167R. M. C. Bastos, A. Simplício-Filho, C. Sávio-Silva, et al., “Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease,” International Journal of Molecular Sciences 23, no. 7 (2022): 3842, https://doi.org/10.3390/ijms23073842.
- 168J. Lu, P. P. Chen, J. X. Zhang, et al., “GPR43 Deficiency Protects Against Podocyte Insulin Resistance in Diabetic Nephropathy Through the Restoration of AMPKα Activity,” Theranostics 11, no. 10 (2021): 4728–4742, https://doi.org/10.7150/thno.56598.
- 169S. Gupta, B. H. Mullish, and J. R. Allegretti, “Fecal Microbiota Transplantation: The Evolving Risk Landscape,” American Journal of Gastroenterology 116, no. 4 (2021): 647–656, https://doi.org/10.14309/ajg.0000000000001075.
- 170C. M. Carvalho, L. A. Gross, M. J. de Azevedo, et al., “Dietary Fiber Intake (Supplemental or Dietary Pattern Rich in Fiber) and Diabetic Kidney Disease: A Systematic Review of Clinical Trials,” Nutrients 11, no. 2 (2019): 347, https://doi.org/10.3390/nu11020347.
- 171L. Luo, J. Luo, Y. Cai, et al., “Inulin-Type Fructans Change the Gut Microbiota and Prevent the Development of Diabetic Nephropathy,” Pharmacological Research 183 (2022): 106367, https://doi.org/10.1016/j.phrs.2022.106367.
- 172M. Timm, L. C. Offringa, B. J.-W. Van Klinken, et al., “Beyond Insoluble Dietary Fiber: Bioactive Compounds in Plant Foods,” Nutrients 15, no. 19 (2023): 194138, https://doi.org/10.3390/nu15194138.
- 173S. Wu, W. Jia, H. He, et al., “A New Dietary Fiber Can Enhance Satiety and Reduce Postprandial Blood Glucose in Healthy Adults: A Randomized Cross-Over Trial,” Nutrients 15, no. 21 (2023): 214569, https://doi.org/10.3390/nu15214569.
- 174M. Niero, G. Bartoli, P. De Colle, et al., “Impact of Dietary Fiber on Inflammation and Insulin Resistance in Older Patients: A Narrative Review,” Nutrients 15, no. 10 (2023): 102365, https://doi.org/10.3390/nu15102365.
- 175H. Lin, J. Li, M. Sun, et al., “Effects of Hazelnut Soluble Dietary Fiber on Lipid-Lowering and Gut Microbiota in High-Fat-Diet-Fed Rats,” International Journal of Biological Macromolecules 256 (2024): 128538, https://doi.org/10.1016/j.ijbiomac.2023.128538.
- 176H. Xu, X. Huang, U. Risérus, et al., “Dietary Fiber, Kidney Function, Inflammation, and Mortality Risk,” Clinical Journal of the American Society of Nephrology 9, no. 12 (2014): 2104–2110, https://doi.org/10.2215/cjn.02260314.
- 177C. Tanes, K. Bittinger, Y. Gao, et al., “Role of Dietary Fiber in the Recovery of the Human Gut Microbiome and Its Metabolome,” Cell Host & Microbe 29, no. 3 (2021): 394–407.e5, https://doi.org/10.1016/j.chom.2020.12.012.
- 178H. Wang, X. Yu, D. Liu, et al., “VDR Activation Attenuates Renal Tubular Epithelial Cell Ferroptosis by Regulating Nrf2/HO-1 Signaling Pathway in Diabetic Nephropathy,” Advanced Science 11, no. 10 (2023): 2305563, https://doi.org/10.1002/advs.202305563.
- 179F. Tian, X. Yi, F. Yang, et al., “Research Progress on the Treatment of Diabetic Nephropathy With Leech and Its Active Ingredients,” Frontiers in Endocrinology 15 (2024): 1296843, https://doi.org/10.3389/fendo.2024.1296843.
- 180T. S. Rasmussen, C. M. J. Mentzel, W. Kot, et al., “Faecal Virome Transplantation Decreases Symptoms of Type 2 Diabetes and Obesity in a Murine Model,” Gut 69, no. 12 (2020): 2122–2130, https://doi.org/10.1136/gutjnl-2019-320005.
- 181T. Luong, A.-C. Salabarria, R. A. Edwards, and D. R. Roach, “Standardized Bacteriophage Purification for Personalized Phage Therapy,” Nature Protocols 15, no. 9 (2020): 2867–2890, https://doi.org/10.1038/s41596-020-0346-0.
- 182G. Fan, F. Cao, T. Kuang, et al., “Alterations in the Gut Virome Are Associated With Type 2 Diabetes and Diabetic Nephropathy,” Gut Microbes 15, no. 1 (2023): 2226925, https://doi.org/10.1080/19490976.2023.2226925.
Citing Literature
